New drug cocktail aims to shrink brain tumors
NCT ID NCT07185373
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 26 times
Summary
This study tests whether adding the targeted drug orelabrutinib to standard chemotherapy improves outcomes for people newly diagnosed with primary central nervous system lymphoma (a rare brain cancer). About 215 adults aged 18-75 will be randomly assigned to one of three treatment groups. The goal is to see which combination best shrinks tumors while keeping side effects manageable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Hematology, Qilu Hospital of Shandong University
Jinan, China
Contact
-
West China Hospital of Sichuan University
Chengdu, China
Contact
Conditions
Explore the condition pages connected to this study.